Latest Breaking News On - Hiroshi kida - Page 1 : comparemela.com

Hokkaido University Development of anti-influenza drugs Sato is a virus specialist with more than 40 years of experience. When he first took up the subject upon joining Shionogi, however, research on drugs to treat viral diseases was not receiving the kind of attention it deserved. In 1974, the world’s first anti-viral drug, Acyclovir, was developed in the United States, but it was not until the discovery of human immunodeficiency virus (HIV) and the development of genetic engineering in the 1980s that research on anti-viral drugs accelerated. After devoting much of his time at Shionogi to researching HIV/AIDS (acquired immune deficiency syndrome) drugs, Sato was assigned to the development of drugs to treat influenza, which is estimated by the World Health Organization (WHO) to cause about 3 million to 5 million cases of severe illness, and about 290,000 to 650,000 respiratory deaths annually worldwide. Hokkaido University was an ideal institution for Shionogi to collaborate wi

United statesHiroshi kidaYoshihiro sakodaBiocryst pharmaceuticalsShionogi innovation centerWorld health organizationResearch centerHokkaido universityZoonosis controlDrug discoveryஒன்றுபட்டது மாநிலங்களில்ஹிரோஷி கீதஉலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்ஆராய்ச்சி மையம்ோக்கைடோ பல்கலைக்கழகம்மருந்து கண்டுபிடிப்பு